Table 1 Summary of clinicopathological features

From: Somatic mutations in leukocytes infiltrating primary breast cancers

ID Age (years) Type Level of lymphocytic infiltration a CD45 (%) Size (cm) HG NG Mitosis OG LVI LN ER PR HER2 FISH
1 40 IDC NOS Moderate 36.6 2 3 3 3 3 No No 0 0 0
2 72 IDC NOS Moderate 11.89 1.5 3 3 3 3 No No 0 0 0
3 b 37 IDC NOS Extensive 12.5 4.5 3 3 3 3 No No <1% <1% 1+ to 2+ 1.3
4 35 IDC NOS Moderate 0.4 5 2 3 3 3 Yes Yes 95% 90% 3+
5 64 ILC (C/P) Minimal 5.0 1 3 3 1 2 No No 99% 10% 1+
6 62 Apocrine Moderate 0.6 3.3 2 3 2 2 Yes Yes 0 0 0
7 83 IDC NOS Moderate 1.4 3.1 3 3 2 3 Yes No 0 0 0
8 35 IDC NOS Moderate 19.1 2.3 3 3 3 3 No No 0 0 0
9 39 IDC NOS Extensive 40.95 3 3 3 3 3 No No 0 0 1+
10 62 IDC NOS Moderate 7.6 1.8 3 3 3 3 Yes No 0 0 1+
11 c 53 IDC NOS Minimal 0.7 1.9 3 3 2 3 No NA 0 0 1+
12 88 Mucinous Moderate 0.3 6.6 2 1 1 1 No Yes 95% 60% 0
13 56 IDC NOS Moderate 1.4 2.5 3 3 3 3 Yes No 5% 5% 3+
14 65 IDC NOS Minimal 1 2.1 3 3 3 3 Yes NA 0 5% 1+
15 72 IDC NOS Moderate 3 1.3 3 3 3 3 No No 0 0 0
  1. Abbreviations: ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HG, histological grade; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LN, lymph node involvement; LVI, lymphovascular invasion; NA, not sampled; NG, nuclear grade; NOS, not otherwise specified; PR, progesterone receptor; TIL, tumor-infiltrating lymphocyte; OG, overall grade.
  2. aScoring criteria for the level of lymphocytic infiltration are defined in PATIENTS AND METHODS.
  3. bPatient with concurrent astrocytoma (WHO III).
  4. cIpsilateral breast cancer recurrence.